Literature DB >> 1545108

Resistance to imipenem among selected gram-negative bacilli in the United States.

R P Gaynes1, D H Culver.   

Abstract

OBJECTIVES: Identification of imipenem resistance among selected gram-negative bacilli, especially Pseudomonas aeruginosa and Enterobacter species.
METHODS: We analyzed 1986-1990 National Nosocomial Infection Surveillance (NNIS) data from 3,316 P aeruginosa isolates and 1,825 Enterobacter species isolates for which susceptibility results to imipenem were reported.
RESULTS: For P aeruginosa, 11.1% of the isolates were resistant to imipenem; 16.1% were either intermediate-susceptible or resistant to the drug. A logistic regression model found that resistance was more common among P aeruginosa isolated from the respiratory tract, patients in intensive care units, and in teaching hospitals. Additionally, resistance to imipenem increased by 25% in teaching hospitals from 1986-1988 to 1989-1990. For Enterobacter species, 1.3% of the isolates were resistant to imipenem; 2.3% were either intermediate-susceptible or resistant to the drug. However, imipenem resistance for these isolates did not differ between the two periods and was not more common in patients in an intensive care unit or infections at any specific site.
CONCLUSIONS: The frequency of resistance to imipenem is greater among P aeruginosa than among Enterobacter species. Resistance to imipenem among the P aeruginosa isolates is more common from strains isolated from patients with nosocomial infections in an intensive care unit, from the respiratory tract, and from teaching hospitals. Resistance appears to be increasing among nosocomial P aeruginosa isolated in teaching hospitals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545108     DOI: 10.1086/646417

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  19 in total

1.  Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa.

Authors:  A C Başustaoğlu; H Gün; M A Saraçli; M Baysallar; T Haznedaroğlu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 2.  An overview of nosocomial infections, including the role of the microbiology laboratory.

Authors:  T G Emori; R P Gaynes
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

3.  Imipenem resistance among gram-negative bacilli.

Authors:  J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Effect of zinc concentration in Mueller-Hinton agar on susceptibility of Pseudomonas aeruginosa to imipenem.

Authors:  J S Daly; R A Dodge; R H Glew; D T Soja; B A DeLuca; S Hebert
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

6.  CG258 Klebsiella pneumoniae isolates without β-lactam resistance at the onset of the carbapenem-resistant Enterobacteriaceae epidemic in New York City.

Authors:  Brandon Eilertson; Liang Chen; Audrey Li; Kalyan D Chavda; Bhakti Chavda; Barry N Kreiswirth
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

7.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.

Authors:  Pinar Onguru; Ayse Erbay; Hurrem Bodur; Gulseren Baran; Esragul Akinci; Neriman Balaban; Mustafa Aydin Cevik
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

10.  Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit.

Authors:  Hatem Kallel; Fouzia Mahjoubi; Hassen Dammak; Mabrouk Bahloul; Chokri Ben Hamida; Hedi Chelly; Noureddine Rekik; Adnéne Hammami; Mounir Bouaziz
Journal:  Indian J Crit Care Med       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.